RUNX1 and cancer: Further analysis of all the enriched pathways upon huATN-658 + Zometa treatment revealed that genes from several crucial pathways related to cancer (for example, ‘Signaling by Nuclear Receptors’; ‘Regulation of nuclear SMAD2/3 signaling’; ‘Beta3 integrin cell surface interactions’; ‘Formation of the beta-catenin: TCF transactivating complex’) and bone remodeling (for example, ‘Transcriptional regulation by RUNX1′; ‘AP-1 transcription factor network’) are differentially regulated (Supplementary File 1, Table S1).